Welcome to our dedicated page for Arteris SEC filings (Ticker: AIP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Arteris, Inc. filings document a semiconductor technology business built around System IP for SoC and chiplet design. Its 8-K reports cover quarterly and annual operating results, financial-condition updates, guidance exhibits, customer shipment milestones, royalty trends and product portfolio disclosures for network-on-chip interconnect IP, SoC integration automation software and hardware security assurance.
The company’s proxy materials cover board elections, executive compensation, equity incentive arrangements and stockholder voting matters. They also describe governance and business context for Arteris’ markets, including automotive, artificial intelligence and machine learning, 5G communications, data centers, edge computing, enterprise and consumer electronics.
Insider sale summary: A Form 4 shows that Paul L. Alpern, Vice President and General Counsel of Arteris, Inc. (AIP), sold a total of 7,627 shares of common stock in two days, 10/02/2025 and 10/03/2025, to satisfy tax obligations arising from the release of restricted stock units and under a previously adopted trading plan. The reported weighted average sale prices ranged from $10.81 to $11.30 with the weighted averages disclosed as $10.9208 and $11.082.
After these dispositions, the reporting person beneficially owned 65,960 shares directly. One tranche of the sales was executed pursuant to a 10b5-1 trading plan adopted on 06/05/2025, and the filer states the sales served to cover tax liabilities from released restricted stock units.
Arteris, Inc. (AIP) reported insider transactions by its Chief Operating Officer. On 10/02/2025, the COO sold 1,885, 891, and 1,926 shares at $10.9208 per share, including shares sold to satisfy tax liabilities from restricted stock unit release. Additional sales under a Rule 10b5-1 trading plan adopted on March 12, 2025 included 19,060 shares at a weighted average price of $10.9908 on 10/02/2025, 1,554 shares at $11.0866 on 10/03/2025, and 17,200 shares at $12.6598 on 10/06/2025.
Following these transactions, the COO beneficially owned 343,885 shares directly.
Arteris (AIP) — Form 4 insider activity: President and CEO K. Charles Janac, who is also a Director and 10% Owner, reported open‑market sales on 10/02/2025 and 10/03/2025. The filing lists sales of 2,767, 1,613, and 2,767 shares at $10.9208, and a separate sale of 11,821 shares at a weighted average price of $11.0705 (with individual trades between $10.80 and $11.29).
One set of shares was sold to satisfy the reporting person’s tax liability from an RSU release, and another transaction was made under a Rule 10b5‑1 trading plan adopted on March 5, 2025. Following the reported transactions, direct holdings were shown as 167,514 shares. Indirect holdings were listed as 9,839,071 shares through Bayview Legacy, LLC and 56,252 shares held by the Charles and Lydia Janac Trust.
Insider sale to cover taxes by Arteris CFO. On 10/02/2025, Nicholas B. Hawkins, the company’s Vice President and Chief Financial Officer, reported three open-market sales of 3,887 shares of Arteris, Inc. (AIP) at an effective price of $10.9208 per share. The three disposals were for 891, 1,508 and 1,488 shares and reduced the reporting person’s direct holdings in stages from 103,007 shares to 100,011 shares following the transactions.
The filing states the shares were sold to satisfy the reporting person’s tax liability triggered by the release of restricted stock units. The Form 4 was signed by an attorney-in-fact on 10/06/2025. No derivative transactions or other types of securities were reported.
Arteris, Inc. director Joachim Kunkel reported receipt of 1,496 shares of common stock as fully vested restricted stock on 10/05/2025. The shares were issued as retainer fees elected in lieu of cash and the reporting person elected to defer receipt; the transaction price is reported as $0.00.
Following the transaction, the reporting person beneficially owns 67,818 shares. The Form 4 was signed by an attorney-in-fact on 10/06/2025 and indicates the filing is by one reporting person and that the reporting person is a director.
Arteris, Inc. reported a Form 144 notice for the proposed sale of 5,755 common shares with an aggregate market value of $63,189.90, showing an approximate sale date of 10/06/2025 on NASDAQ. The securities were originally acquired on 06/16/2014 in a private acquisition from the issuer and paid for in cash. The filing lists multiple recent dispositions by the related party, including several 10b5-1 sales and direct sales by K. CHARLES JANAC totalling sizeable proceeds in August–October 2025 (examples: $1,271,120.01 for 94,245 shares on 08/05/2025; $655,995.00 for 50,000 shares on 08/05/2025). The filing includes the required representation that the seller is not aware of undisclosed material adverse information.
Arteris, Inc. insider notice reports a proposed sale under Rule 144 of 11,841 common shares with an aggregate market value of $130,014.18. The shares were acquired on 01/28/2021 through previously exercised stock options and were paid for in cash. The filing names Morgan Stanley Smith Barney LLC Executive Financial Services as the broker and lists an approximate sale date of 10/06/2025 on NASDAQ. The notice also discloses a prior sale on 08/05/2025 of 6,909 shares generating $97,699.48, and includes the standard Rule 10b5-1 representation and signature attestation.
Notice of proposed insider sale: This Form 144 reports a planned sale of 17,200 common shares through Morgan Stanley Smith Barney LLC with an aggregate market value of $188,856.00. The shares were acquired as Restricted Stock Units on 09/03/2024 and listed as available for sale with an approximate sale date of 10/06/2025 on NASDAQ. The filing also discloses multiple recent sales by the same person under 10b5-1 plans totaling tens of thousands of shares across 07/29/2025 through 10/03/2025, with individual gross proceeds shown per trade. The filer represents they know of no undisclosed material adverse information.
Arteris, Inc. (AIP) filed a Form 144 reporting a proposed Rule 144 sale of 100,000 common shares through Morgan Stanley Smith Barney LLC on the 10/06/2025, with an aggregate market value of $1,098,000.00 based on the filing. The shares were acquired in a private issuance from the issuer on 11/05/2013 and the filing says payment was made by check on that date.
The filing also discloses multiple sales by the same person (and related 10b5-1 plans) during the past three months, including a 94,245-share 10b5-1 sale on 08/05/2025 and other transactions totaling material proceeds. The filer attests they have no undisclosed material adverse information.
Arteris, Inc. filing of Form 144 notifies the market of a proposed sale of 4,750 common shares through Morgan Stanley Smith Barney LLC with an aggregate market value of $53,485.00. The sale is to occur on or about 10/03/2025 on NASDAQ. The shares were acquired as Restricted Stock Units on 10/01/2025 from the issuer and are listed as 4,750 units in the notice. The filing also discloses multiple recent sales by the same person, Paul Alpern, during the past three months with individual sale dates and proceeds provided.
The form includes the seller's representation that no undisclosed material adverse information is known and provides broker contact details; it documents compliance with Rule 144 sale notice requirements rather than presenting operational or financial performance data.